HC invalidates Gujarat education minister’s 2017 election win for malpractice

Bijnor: A 17-year-old Dalit youth was shot dead by four miscreants belonging to the upper caste of Hinduism after the former tried to enter a temple in Uttar Pradesh.

The deceased was identified as Vikas Jatav. The accused had tried to stop the deceased from entering into a temple. 

On being stopped from entering the temple located in Domkhera village, Jatav raised and objection and started arguing with the accused. 

The accused were identified as - Lala Chauhan, Horam Chauhan, Bhushan and Jasveer. The incident took place on May 31, according to the father of the deceased. 

How it happened 
On May 31, Jatav went to a temple in Domkhera to offer his prayers. The four accused, however, did not let him go inside. Following this, an argument broke out between the accused and the 17-year-old boy. 

On the same day, the victim approached the police and lodged a complaint in relation to the incident. The police, however, did not take any action against the accused men. 

Late night on Saturday, Jatav was sleeping inside his house when the four men barged in and opened fire at him. 

Hearing the gunshots, Jatav's family rushed to rescue him, following which, the accused escaped. Vikas was profusely bleeding after being shot and succumbed to the injuries before he could reach the hospital. 

Lala Chauhan and Horam were nabbed by the police while the other two are still at large. The four accused have been booked under section 302 (murder) of the Indian Penal Code (IPC) and the SC/ST Act.

New Delhi, Jun 24: With the highest single-day spike of 15,968 cases and 465 deaths in the last 24 hours, India's COVID-19 count reached 4,56,183 on Wednesday.

According to the latest update by the Union Ministry of Health and Family Welfare (MoHFW), 14,476 deaths have been recorded due to the infection so far in the country.

The count includes 1,83,022 active cases, and 2,58,685 cured/discharged/migrated patients.

Maharashtra with 1,39,010 confirmed cases remains the worst-affected by the infection so far in the country. The state's count includes 62,848 active, 69,631 cured, discharged patients while 6,531 deaths have been reported due to the infection so far.

Meanwhile, the national capital's confirmed coronavirus cases reached 66,602.

2,301 deaths have been reported in Delhi due to the infection so far.

Tamil Nadu has reported 64,603 cases so far with the death toll reaching 833.

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.